Note 8 - Noncontrolling Interest - Clyra Medical (Tables)
|
3 Months Ended |
Mar. 31, 2026 |
| Notes Tables |
|
| Schedule of Other Ownership Interests [Table Text Block] |
| | | Clyra Options Outstanding | | | Weighted average price per share | | | Weighted average remaining life | |
| Balance, December 31, 2024 | | | 1,976,863 | | | $ | 1.00 | | | | | |
| Granted | | | 25,332 | | | $ | 4.50 | | | | | |
| Balance, March 31, 2025 | | | 2,002,195 | | | $ | 1.04 | | | | | |
| Unvested | | | (250,000 | ) | | $ | 0.01 | | | | | |
| Vested Balance, March 31, 2025 | | | 1,752,195 | | | $ | 1.19 | | | | | |
| | | | | | | | | | | | | |
| Balance, December 31, 2025 | | | 3,013,692 | | | $ | 2.17 | | | | | |
| Granted | | | 164,242 | | | $ | 4.44 | | | | | |
| Balance, March 31, 2026 | | | 3,177,934 | | | $ | 2.29 | | | | 7.2 | |
| Unvested | | | (760,678 | ) | | $ | 4.06 | | | | | |
| Vested Balance, March 31, 2026 | | | 2,417,256 | | | $ | 1.74 | | | | 8.1 | |
|
| Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] |
| | | 2026 | | | 2025 | |
| | | Non Plan | | | 2024 Plan | | | Non Plan | | | 2024 Plan | |
| Risk free interest rate | | | — | | | | 4.30 | % | | | 4.23 | % | | | 4.23 - 4.58 | % |
| Expected volatility | | | — | | | | 84 | % | | | 91 | % | | | 91 | % |
| Expected dividend yield | | | — | | | | — | | | | — | | | | — | |
| Forfeiture rate | | | — | | | | — | | | | — | | | | — | |
| Life in years | | | — | | | | 10 | | | | 10 | | | | 10 | |
|
| Warrants Outstanding for Noncontrolling Interest [Table Text Block] |
| | | Clyra Warrants Outstanding | | | Weighted average price per share | | | Weighted average remaining life | |
| Balance, December 31, 2024 | | | 1,183,182 | | | $ | 4.84 | | | | | |
| Granted | | | 125,917 | | | $ | 6.40 | | | | | |
| Vested Balance, March 31, 2025 | | | 1,309,099 | | | $ | 4.99 | | | | | |
| | | | | | | | | | | | | |
| Balance, December 31, 2025 | | | 1,702,496 | | | $ | 5.39 | | | | | |
| Granted | | | 159,668 | | | $ | 7.50 | | | | | |
| Expired | | | (40,323 | ) | | $ | 3.72 | | | | | |
| Vested Balance, March 31, 2026 | | | 1,821,841 | | | $ | 5.61 | | | | 1.7 | |
|
| Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] |
| Category | | BioLargo | | | ONM | | | BLEST | | | BioLargo Canada | | | BETI | | | BEST | | | Intercompany amounts | | | Totals | |
| Accounts payable | | $ | 428 | | | $ | 274 | | | $ | 15 | | | $ | 119 | | | $ | 5 | | | $ | — | | | $ | (3 | ) | | $ | 838 | |
| Accrued payroll | | | 10 | | | | 103 | | | | 94 | | | | 21 | | | | — | | | | 10 | | | | — | | | | 238 | |
| Total | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | $ | 1,076 | |
| Category | | BioLargo | | | ONM | | | BLEST | | | BioLargo Canada | | | BETI | | | BEST | | | Intercompany amounts | | | Totals | |
| Accounts payable | | $ | 588 | | | $ | 305 | | | $ | — | | | $ | 100 | | | | 43 | | | $ | — | | | $ | (24 | ) | | $ | 1,012 | |
| Accrued payroll | | | 10 | | | | 85 | | | | 73 | | | | 22 | | | | — | | | | 9 | | | | — | | | | 199 | |
| Total | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | $ | 1,211 | |
|
| Clyra Medical [Member] |
|
| Notes Tables |
|
| Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] |
| Category | | 2026 | | | 2025 | |
| Accounts payable | | $ | 454 | | | $ | 634 | |
| Accrued dividend | | | 1,023 | | | | 937 | |
| Accrued payroll | | | 33 | | | | 21 | |
| Total | | $ | 1,510 | | | $ | 1,592 | |
|
| Finance Lease, Liability, to be Paid, Maturity [Table Text Block] |
| Year ending | | | | |
| December 31, 2026 | | $ | 112 | |
| December 31, 2027 | | | 150 | |
| December 31, 2028 | | | 150 | |
| Total minimum lease payments | | $ | 412 | |
| Less imputed interest | | | (76 | ) |
| Total finance lease liabilities | | $ | 336 | |
|
| Clyra Medical Technologies [Member] |
|
| Notes Tables |
|
| Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] |
| | | March 31, 2026 | | | March 31, 2025 | |
| Risk free interest rate | | | 4.20 - 4.36 | % | | | 4.45 | % |
| Expected volatility | | | 35 - 39 | % | | | 43 | % |
| Expected dividend yield | | | — | | | | — | |
| Forfeiture rate | | | — | | | | — | |
| Expected life in years | | | 10 | | | | 10 | |
|